American Heart Journal
Volume 156, Issue 2 , Pages 269-276 , August 2008

Additive prognostic value of interleukin-6 at peak phase of dobutamine stress echocardiography in patients with coronary artery disease. A 6-year follow-up study

  • Ignatios Ikonomidis, MD

      Affiliations

    • 2nd Cardiology Department, Attikon Hospital, University of Athens, Athens, Greece
    • Corresponding Author InformationReprint requests: Ignatios Ikonomidis, MD, 2nd Cardiology Department, Attikon Hospital, University of Athens, Perikleous 19, Athens 14343, Greece.
    • ,
  • George Athanassopoulos, MD

      Affiliations

    • 1st Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece
    • ,
  • Kimon Stamatelopoulos, MD

      Affiliations

    • Department of Cardiology, Hammersmith Hospital, The Imperial College School of Medicine, London, UK
    • ,
  • John Lekakis, MD

      Affiliations

    • 2nd Cardiology Department, Attikon Hospital, University of Athens, Athens, Greece
    • ,
  • Ioanna Revela, MD

      Affiliations

    • 2nd Cardiology Department, Attikon Hospital, University of Athens, Athens, Greece
    • ,
  • Kiriaki Venetsanou, MD

      Affiliations

    • 2nd Cardiology Department, Attikon Hospital, University of Athens, Athens, Greece
    • ,
  • Margarita Marinou, MD

      Affiliations

    • 1st Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece
    • ,
  • Claudia Monaco, MD

      Affiliations

    • Department of Cardiology, Hammersmith Hospital, The Imperial College School of Medicine, London, UK
    • ,
  • Dennis V. Cokkinos, MD

      Affiliations

    • 1st Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece
    • ,
  • Petros Nihoyannopoulos, MD

      Affiliations

    • Department of Cardiology, Hammersmith Hospital, The Imperial College School of Medicine, London, UK

Received 22 January 2008 ,Accepted 20 March 2008.

References 

  1. Pingitore A, Picano E, Varga A, et al. Prognostic value of pharmacological stress echocardiography in patients with known or suspected coronary artery disease: a prospective, large-scale, multicenter, head-to-head comparison between dipyridamole and dobutamine test. J Am Coll Cardiol. 1999;34:1769–1777
  2. Marwick T, Case C, Sawada S, et al. Prediction of mortality using dobutamine echocardiography. J Am Coll Cardiol. 2001;37:754–760
  3. Biagini E, Elhendy A, Bax J, et al. Seven-year follow-up after dobutamine stress echocardiography. Impact of gender on prognosis. J Am Coll Cardiol. 2005;45:93–97
  4. Sicari R, Pasanisi E, Venneri L, et al. Stress echo results predict mortality: a large-scale multicenter prospective international study. J Am Coll Cardiol. 2003;41:589–595
  5. Tsutsui JM, Elhendy A, Anderson JR, et al. Prognostic value of dobutamine stress myocardial contrast perfusion echocardiography. Circulation. 2005;112:1444–1450
  6. Bjork Ingul C, Rozis E, Slordahl SA, et al. Incremental value of strain rate imaging to wall motion analysis for prediction of outcome in patients undergoing dobutamine stress echocardiography. Circulation. 2007;115:1252–1259
  7. Sozzi FB, Elhendy A, Roelandt JR, et al. Long-term prognosis after normal dobutamine stress echocardiography. Am J Cardiol. 2003;92:1267–1270
  8. Ikonomidis I, Stamatelopoulos K, Lekakis J, et al. Inflammatory markers in coronary artery disease: pathophysiological mechanisms, prognostic and therapeutic implications. Curr Cardiol Rev. 2006;2:173–184
  9. Koukkunen H, Penttila K, Kemppainen A, et al. C-Reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med. 2001;33:37–47
  10. Fisman EZ, Benderly M, Esper RJ, et al. Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. Am J Cardiol. 2006;98:14–18
  11. Hoffmeister A, Rothenbacher D, Kunze M, et al. Prognostic value of inflammatory markers alone and in combination with blood lipids in patients with stable coronary artery disease. Eur J Intern Med. 2005;16:47–52
  12. Ikonomidis I, Athanassopoulos G, Lekakis J, et al. Myocardial ischaemia induces interleukin 6 and tissue factor production in patients with coronary artery disease. A dobutamine stress echocardiography study. Circulation. 2005;112:3272–3279
  13. Finkel MS, Hoffman RA, Shen L, et al. Interleukin 6 as a mediator of stunned myocardium. Am J Cardiol. 1993;71:1231–1232
  14. Tsoukas A, Ikonomidis I, Cokkinos P, et al. Significance of persistent left ventricular dysfunction during recovery after dobutamine stress echocardiography. J Am Coll Cardiol. 1997;30:621–626
  15. Sawada SG, Segar DS, Ryan T, et al. Echocardiographic detection of coronary artery disease during dobutamine infusion. Circulation. 1991;83:1605–1614
  16. Hoffmann R, Lethen H, Kühl H, et al. Extent and severity of test positivity during dobutamine stress echocardiography: influence on the predictive value for coronary artery disease. Eur Heart J. 1999;20:1485–1492
  17. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003;107:149–158
  18. Juul-Mollers S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340:1421–1425
  19. Picano E, Lattanzi F, Orlandini A, et al. Stress echocardiography and the human factor: the importance of being expert. J Am Coll Cardiol. 1991;17:666–669
  20. Wassmann S, Stumpf M, Strehlow K, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 2004;94:534–541
  21. Szotowski B, Antoniak S, Poller W, et al. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ. Res. 2005;96:1233–1239
  22. Kukielka GL, Smith CW, Manning AM, et al. Induction of interleukin-6 synthesis in the myocardium. Potential role in post-perfusion inflammatory injury. Circulation. 1995;92:1866–1875
  23. Deng MC, Erren M, Lütgen A, et al. Interleukin 6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure. Int J Cardiol. 1996;57:129–134
  24. James SK, Oldgren J, Lindbäck J, et al. An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. Am Heart J. 2005;149:619–626
  25. Deliargyris E, Raymond RJ, Theoharides TC, et al. Sites of interleukin 6 in patients with acute coronary syndromes and in patients with congestive heart failure. Am J Cardiol. 2000;86:913–918
  26. The Heart Outcomes Prevention Evaluation Study Investigators . Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153

PII: S0002-8703(08)00230-5

doi: 10.1016/j.ahj.2008.03.020

American Heart Journal
Volume 156, Issue 2 , Pages 269-276 , August 2008

Article Tools

* Image Usage & Resolution